Results 31 to 40 of about 1,458 (171)

Molecular selection of therapy in metastatic colorectal cancer: the FOCUS4 molecularly stratified RCT

Efficacy and Mechanism Evaluation, 2022
Background: Complex trials with innovative designs are becoming increasingly common and offer the potential to improve patient outcomes in a shorter time frame.
Louise C Brown, David Fisher, Richard Adams, Jenny Seligmann, Matthew Seymour, Richard Kaplan, Susan D Richman, Philip Quirke, Rachel Butler, Helen Roberts, Janet Graham, Richard H Wilson, Timothy S Maughan   +12 more
doaj   +1 more source

Increased HDAC Activity and c-MYC Expression Mediate Acquired Resistance to WEE1 Inhibition in Acute Leukemia

Frontiers in Oncology, 2020
WEE1 is a cell cycle and DNA damage response kinase that is emerging as a therapeutic target for cancer. AZD1775 is a small molecule inhibitor of WEE1, currently in early phase clinical trials as a single agent and in combination with more conventional ...
Tamara B. Garcia, Rizvan C. Uluisik, Annemie A. van Linden, Kenneth L. Jones, Sujatha Venkataraman, Rajeev Vibhakar, Christopher C. Porter   +6 more
doaj   +1 more source

Codelivery of adavosertib and olaparib by tumor-targeting nanoparticles for augmented efficacy and reduced toxicity

Acta Biomaterialia, 2023
Ovarian cancer (OC) ranks first among gynecologic malignancies in terms of mortality. The benefits of poly (ADP-ribose) polymerase (PARP) inhibitors appear to be limited to OC with BRCA mutations. Concurrent administration of WEE1 inhibitors (eg, adavosertib (Ada)) and PARP inhibitors (eg, olaparib (Ola)) effectively suppress ovarian tumor growth ...
Wei Wang, Yuxuan Xiong, Xingyuan Hu, Funian Lu, Tianyu Qin, Li Zhang, Ensong Guo, Bin Yang, Yu Fu, Dianxing Hu, JunPeng Fan, Xu Qin, Chen Liu, RouRou Xiao, Gang Chen, Zifu Li, Chaoyang Sun   +16 more
openaire   +2 more sources

Transcription termination counteracts DNA damage after WEE1 inhibition. [PDF]

Nucleic Acids Res
Transcription termination is a key regulatory step in transcription and a potential target for cancer therapy, but how it can be exploited for treatment is incompletely understood.
Landsverk HB, Sandquist LE, Bay LTE, Hauge S, van Bijsterveldt L, Lindbergsengen L, Lund-Andersen C, Kanduri C, Lyng H, Fjeldbo CS, Hompland T, Humphrey TC, Syljuåsen RG.   +12 more
europepmc   +2 more sources

Transcriptionally distinct malignant neuroblastoma populations show selective response to adavosertib treatment. [PDF]

Neurotherapeutics
Neuroblastoma is an aggressive childhood cancer that arises from the sympathetic nervous system. Despite advances in treatment, high-risk neuroblastoma remains difficult to manage due to its heterogeneous nature and frequent development of drug resistance. Drug repurposing guided by single-cell analysis presents a promising strategy for identifying new
Hsieh CH, Chen YX, Tseng TY, Li A, Huang HC, Juan HF.   +5 more
europepmc   +3 more sources

Adavosertib with Chemotherapy in Patients with Primary Platinum-Resistant Ovarian, Fallopian Tube, or Peritoneal Cancer: An Open-Label, Four-Arm, Phase II Study

, 2021
Purpose: This study assessed the efficacy, safety, and pharmacokinetics of adavosertib in combination with four chemotherapy agents commonly used in patients with primary platinum-resistant ovarian cancer.
Cadoo, Karen A, Mugundu, Ganesh M, Kumar, Sanjeev, Cragun, Janiel M, Spigel, David R, Rodrigo Imedio, Esteban, Moore, Kathleen N, Hamilton, Erika P, Konecny, Gottfried E, Plaxe, Steven C, Lai, Zhongwu, Oza, Amit M, Ghamande, Sharad A, Troso-Sandoval, Tiffany A, Jones, Suzanne F, Chambers, Setsuko K, Spitz, Daniel L, Geenen, Jill J J, Chen, Lee-May, Chmielecki, Juliann, Sharad A. Ghamande, Sanjeev Kumar, David R. Spigel, Jill J.J. Geenen, Gottfried E. Konecny, Steven C. Plaxe, Daniel L. Spitz, Zhongwu Lai, Amit M. Oza, Janiel M. Cragun, Karen A. Cadoo, Tiffany A. Troso-Sandoval, Esteban Rodrigo Imedio, Ganesh M. Mugundu, Erika P. Hamilton, Setsuko K. Chambers, Juliann Chmielecki, Lee-may Chen, Kathleen N. Moore, Suzanne F. Jones   +39 more
core   +1 more source

Exploiting collateral sensitivity controls growth of mixed culture of sensitive and resistant cells and decreases selection for resistant cells in a cell line model

Cancer Cell International, 2020
Background CDK4/6 inhibitors such as ribociclib are becoming widely used targeted therapies in hormone-receptor-positive (HR+) human epidermal growth factor receptor 2-negative (HER2−) breast cancer. However, cancers can advance due to drug resistance, a
Vince Kornél Grolmusz, Jinfeng Chen, Rena Emond, Patrick A. Cosgrove, Lance Pflieger, Aritro Nath, Philip J. Moos, Andrea H. Bild   +7 more
doaj   +1 more source

Combined PARP and WEE1 inhibition triggers anti-tumor immune response in BRCA1/2 wildtype triple-negative breast cancer

npj Breast Cancer, 2023
Novel therapeutic strategies that can effectively combine with immunotherapies are needed in the treatment of triple-negative breast cancer (TNBC). We demonstrate that combined PARP and WEE1 inhibition are synergistic in controlling tumour growth in ...
Zhi Ling Teo, Mark J. O’Connor, Stephanie Versaci, Kylie A. Clarke, Emmaline R. Brown, Luke W. Percy, Keilly Kuykhoven, Christopher P. Mintoff, Peter Savas, Balaji Virassamy, Stephen J. Luen, Ann Byrne, Sneha Sant, Geoffrey J. Lindeman, Phillip K. Darcy, Sherene Loi   +15 more
doaj   +1 more source

Targeting WEE1 Inhibits Growth of Breast Cancer Cells That Are Resistant to Endocrine Therapy and CDK4/6 Inhibitors

Frontiers in Oncology, 2021
Despite the success of antiestrogens in extending overall survival of patients with estrogen receptor positive (ER+) breast tumors, resistance to these therapies is prevalent.
Yassi Fallah, Diane M. Demas, Lu Jin, Wei He, Ayesha N. Shajahan-Haq   +4 more
doaj   +1 more source

G2 checkpoint targeting via Wee1 inhibition radiosensitizes EGFRvIII-positive glioblastoma cells

Radiation Oncology, 2023
Background The gene of the Epidermal growth factor receptor (EGFR) is one of the most frequently altered genes in glioblastoma (GBM), with deletions of exons 2–7 (EGFRvIII) being amongst the most common genomic mutations.
Meryem H. Cetin, Thorsten Rieckmann, Konstantin Hoffer, Britta Riepen, Sabrina Christiansen, Fruzsina Gatzemeier, Simon Feyerabend, Melanie Schoof, Ulrich Schüller, Cordula Petersen, Martin Mynarek, Kai Rothkamm, Malte Kriegs, Nina Struve   +13 more
doaj   +1 more source